Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jul;87(1):82-84.
doi: 10.1016/j.jinf.2023.04.019. Epub 2023 May 3.

Casirivimab-imdevimab treatment is associated with reduced rates of mortality and hospitalization in patients with COVID-19: A systematic review with meta-analysis

Ming Gao  1 , Guangyu Ao  2 , Xiaodan Hao  3 , Bo Xie  4
Affiliations
Comment

Casirivimab-imdevimab treatment is associated with reduced rates of mortality and hospitalization in patients with COVID-19: A systematic review with meta-analysis

Ming Gao et al. J Infect. 2023 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no competing interest.

Figures

Fig. 1
Fig. 1
A. Association between casirivimab-imdevimab treatment and mortality, B. Association between casirivimab-imdevimab treatment and hospitalization.
See this image and copyright information in PMC

Comment on

References

    1. Wang Y., Zheng J., Zhu K., Xu C., Wang D., Ho M. The effect of tixagevimab-cilgavimab on clinical outcomes in patients with COVID-19: a systematic review with meta-analysis. J Infect. 2023;86(1):e15–e17. doi: 10.1016/j.jinf.2022.08.021. - DOI - PMC - PubMed
    1. Razonable R.R., Pawlowski C., O'Horo J.C., Arndt L.L., Richard Arndt R., Bierle D.M., et al. Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. eClinicalMedicine. 2021;40 doi: 10.1016/j.eclinm.2021.101102. - DOI - PMC - PubMed
    1. Joy A.P., Karattuthodi M.S., Chandrasekher D., Augustine. A.T. The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: a retro-prospective comparative study in India. J Assoc Physicians India. 2022;70(4):11–12. - PMC - PubMed
    1. Hussein M., Wei W., Mastey V., Sanchez R.J., Wang D., Murdock D.J., et al. Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory setting: a retrospective cohort study using a large claims database. BMJ Open. 2022;12(12) doi: 10.1136/bmjopen-2022-064953. - DOI - PMC - PubMed
    1. McCreary E.K., Bariola J.R., Wadas R.J., Shovel J.A., Wisniewski M.K., Adam M., et al. Association of subcutaneous or intravenous administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in adults with COVID-19. JAMA Netw Open. 2022;5(4) doi: 10.1001/jamanetworkopen.2022.6920. - DOI - PMC - PubMed

Substances